Evalon

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

ваксина срещу кокцидиоза при пилета

Available from:

Laboratorios Hipra, S.A.

ATC code:

QI01AN01

INN (International Name):

eimeria acervulina, strain 003, eimeria brunetti, strain 034, eimeria maxima, strain 013, eimeria necatrix, strain 033, eimeria tenella, strain 004

Therapeutic group:

Пиле

Therapeutic area:

Да живее паразитные ваксина, имуномодулатори за птици

Therapeutic indications:

За активна имунизация на пилета от 1 ден на възрастта за намаляване на клиничните прояви (диария), лезии на червата ооцисти са и изход, свързани с кокцидиоза, причинени от Эймери acervulina, Эймери брунетти, Эймери Максим, Эймери necatrix и Эймери tenella.

Product summary:

Revision: 2

Authorization status:

упълномощен

Authorization date:

2016-04-18

Patient Information leaflet

                                17
B. ЛИСТОВКА
18
ЛИСТОВКА:
EVALON СУСПЕНЗИЯ И РАЗТВОРИТЕЛ ЗА
ПЕРОРАЛЕН СПРЕЙ ЗА ПИЛЕТА
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба и
производител, отговорен за
освобождаване на партидата:
Laboratorios Hipra, S.A.
Avda. la Selva 135
17170 Amer (Girona)
SPAIN
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Evalon суспензия и разтворител за
перорален спрей за пилета.
3.
СЪДЪРЖАНИЕ НА АКТИВНИТЕ СУБСТАНЦИИ И
ЕКСЦИПИЕНТИТЕ
Evalon
Активни субстанции:
Всяка доза (0,007 ml) от неразредена
ваксина съдържа
_Eimeria acervulina, _
щам 003 ....................................... 332 – 450*
_Eimeria brunetti, _
щам 034 ........................................... 213 – 288*
_Eimeria maxima, _
щам 013 ........................................... 196 – 265*
_Eimeria necatrix, _
щам 033 ........................................... 340 – 460*
_Eimeria tenella, _
щам 004 ............................................. 276 – 374*
* Брой спорулирани ооцисти, получени
от преждевременно развили се
отслабени линии на
кокцидии, според
_in vitro_
процедурите на производителя в
момента на смесване.
HIPRAMUNE T (разтворител)
АДЖУВАНТ:
Монтанид IMS
ЕКСЦИПИЕНТИ:
Брилянтно синьо (Е133)
Алура червено AC (E129)
Ванилин
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
За активна имунизация на пиленца на
възра
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Evalon суспензия и разтворител за
перорален спрей за пилета.
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Evalon:
Всяка доза (0,007 ml) неразредена ваксина
съдържа:
АКТИВНИ СУБСТАНЦИИ:
_Eimeria acervulina, _
щам 003 ....................................... 332 – 450*
_Eimeria brunetti, _
щам 034 ........................................... 213 – 288*
_Eimeria maxima, _
щам 013 ........................................... 196 – 265*
_Eimeria necatrix, _
щам 033 ........................................... 340 – 460*
_Eimeria tenella, _
щам 004 ............................................. 276 – 374*
* Брой спорулирани ооцисти, получени
от преждевременно развили се
отслабени линии на
кокцидии, според
_in vitro_
процедурите на производителя в
момента на смесване.
HIPRAMUNE T (разтворител):
АДЖУВАНТ:
Монтанид IMS
ЕКСЦИПИЕНТИ:
Брилянтно синьо (Е133)
Алура червено AC (E129)
Ванилин
За пълния списък на ексципиентите, виж
т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Суспензия и разтворител за перорален
спрей.
Суспензия: бяла мътна суспензия.
Разтворител: тъмнокафеникав разтвор.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Пилета.
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОПРЕДЕЛЕНИ ЗА
ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
За активна имунизация на пиле
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 26-02-2021
Public Assessment Report Public Assessment Report Spanish 13-05-2016
Patient Information leaflet Patient Information leaflet Czech 26-02-2021
Public Assessment Report Public Assessment Report Czech 13-05-2016
Patient Information leaflet Patient Information leaflet Danish 26-02-2021
Public Assessment Report Public Assessment Report Danish 13-05-2016
Patient Information leaflet Patient Information leaflet German 26-02-2021
Public Assessment Report Public Assessment Report German 13-05-2016
Patient Information leaflet Patient Information leaflet Estonian 26-02-2021
Public Assessment Report Public Assessment Report Estonian 13-05-2016
Patient Information leaflet Patient Information leaflet Greek 26-02-2021
Public Assessment Report Public Assessment Report Greek 13-05-2016
Patient Information leaflet Patient Information leaflet English 26-02-2021
Public Assessment Report Public Assessment Report English 13-05-2016
Patient Information leaflet Patient Information leaflet French 26-02-2021
Public Assessment Report Public Assessment Report French 13-05-2016
Patient Information leaflet Patient Information leaflet Italian 26-02-2021
Public Assessment Report Public Assessment Report Italian 13-05-2016
Patient Information leaflet Patient Information leaflet Latvian 26-02-2021
Public Assessment Report Public Assessment Report Latvian 13-05-2016
Patient Information leaflet Patient Information leaflet Lithuanian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-02-2021
Public Assessment Report Public Assessment Report Lithuanian 13-05-2016
Patient Information leaflet Patient Information leaflet Hungarian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 26-02-2021
Public Assessment Report Public Assessment Report Hungarian 13-05-2016
Patient Information leaflet Patient Information leaflet Maltese 26-02-2021
Public Assessment Report Public Assessment Report Maltese 13-05-2016
Patient Information leaflet Patient Information leaflet Dutch 26-02-2021
Public Assessment Report Public Assessment Report Dutch 13-05-2016
Patient Information leaflet Patient Information leaflet Polish 26-02-2021
Public Assessment Report Public Assessment Report Polish 13-05-2016
Patient Information leaflet Patient Information leaflet Portuguese 26-02-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 26-02-2021
Public Assessment Report Public Assessment Report Portuguese 13-05-2016
Patient Information leaflet Patient Information leaflet Romanian 26-02-2021
Public Assessment Report Public Assessment Report Romanian 13-05-2016
Patient Information leaflet Patient Information leaflet Slovak 26-02-2021
Public Assessment Report Public Assessment Report Slovak 13-05-2016
Patient Information leaflet Patient Information leaflet Slovenian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 26-02-2021
Public Assessment Report Public Assessment Report Slovenian 13-05-2016
Patient Information leaflet Patient Information leaflet Finnish 26-02-2021
Public Assessment Report Public Assessment Report Finnish 13-05-2016
Patient Information leaflet Patient Information leaflet Swedish 26-02-2021
Public Assessment Report Public Assessment Report Swedish 13-05-2016
Patient Information leaflet Patient Information leaflet Norwegian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 26-02-2021
Patient Information leaflet Patient Information leaflet Icelandic 26-02-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 26-02-2021
Patient Information leaflet Patient Information leaflet Croatian 26-02-2021
Public Assessment Report Public Assessment Report Croatian 13-05-2016

View documents history